| Prev Close | 3.57 |
| Open | 3.56 |
| Day Low/High | 3.42 / 3.56 |
| 52 Wk Low/High | 1.68 / 5.88 |
| Volume | 34.23K |
| Avg Volume | 363.50K |
| Exchange | NASDAQ |
| Shares Outstanding | 2.37M |
| Market Cap | 9.09M |
| EPS | -5.50 |
| P/E Ratio | 0.52 |
| Div & Yield | N.A. (N.A) |
Latest News
Lpath Completes Dosing In The Lpathomab Phase 1 Safety Study
Lpathomab is well-tolerated at all doses tested in healthy volunteers
Lpath To Hold Corporate Update Conference Call And Live Webcast On Tuesday, November 17th
Company to Present Additional Data From the Nexus Phase 2 Study of iSONEP™
Lpath Announces Plan To Begin Lpathomab Clinical Trial
Company Provides Update on Strategic Priorities
5 Stocks Under $10 Set to Soar
These under-$10 stocks look poised to trade higher from current levels. Here's how to trade them.
4 Big-Volume Stocks Triggering Breakout Trades
These stocks rising on unusual volume are within range of triggering breakout trades.
Lpath Reports Results For ISONEP™ In Patients With Wet Age-related Macular Degeneration
Study Did Not Meet Primary or Key Secondary Endpoints
Lpath Reports Results For ASONEP Phase 2a Study In Renal Cell Carcinoma
Conference Call Scheduled for Today at 4:30 p.m. ET to Provide Investor Update
Lpath Completes Enrollment In Its Phase 2 Clinical Trial Of ISONEP For Wet Age-Related Macular Degeneration
Conference Call Scheduled for Wednesday, December 3rd to Provide Investor Update
Lpath Announces Departure Of CEO
Scott Pancoast Resigns as President & CEO; Board Appoints Michael Lack as Interim CEO
Lpath Granted Key European Patent Related To ISONEP And ASONEP Programs
Patent Provides Coverage for Lpath's Anti-S1P Antibody in Europe
Lpath Reports Interim Data From Phase 2a Study For Anti-Cancer Drug, ASONEP
Based on encouraging progression-free survival data, Lpath extends the study to a second cohort and considers additional proof-of-concept studies
3 Stocks Pushing The Health Care Sector Lower
TheStreet highlights 3 stocks pushing the Health Care sector lower today.
Lpath Lands Fast-Track SBIR Grant From The NIH For Traumatic Brain Injury Treatment
SBIR Grant from the National Institutes of Neurological Diseases and Stroke Provides Funds for IND-enabling Studies of Lpathomab
Lpath And Walter Reed Army Institute For Research Begin Efficacy Study Using Lpathomab In Traumatic Brain Injury Models
The Department of Defense's WRAIR will study Lpath's anti-LPA antibody in the blast injury model of TBI
3 Stocks Under $10 to Watch
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.